Tulay Kus1, Gokmen Aktas2, Gokay Alpak3, Mehmet Emin Kalender2, Alper Sevinc2, Seval Kul4, Mithat Temizer5, Celaletdin Camci2. 1. Department of Internal Medicine, Division of Medical Oncology, Gaziantep Oncology Hospital, University of Gaziantep, TR-27310, Gaziantep, Turkey. drtulaykus83@hotmail.com. 2. Department of Internal Medicine, Division of Medical Oncology, Gaziantep Oncology Hospital, University of Gaziantep, TR-27310, Gaziantep, Turkey. 3. Department of Psychiatry, University of Gaziantep, TR-27310, Gaziantep, Turkey. 4. Department of Biostatistics, Faculty of Medicine, University of Gaziantep, TR-27310, Gaziantep, Turkey. 5. Department of Public Health, University of Gaziantep, TR-27310, Gaziantep, Turkey.
Abstract
BACKGROUND: Oxaliplatin and taxane-induced neurosensory toxicity is dose-limiting and mostly presents with acute symptoms that affect the activities of daily living and overall quality of life. The objective of the present study is to assess the relief of acute neuropathy with venlafaxine treatment during the chemotherapy period. PATIENTS AND METHODS: In this retrospective case-control study, from January 2010 to February 2015, patients who experienced treatment with oxaliplatin and taxane-induced acute neurotoxicity were evaluated according to the NCI-CTCAE v. 4.03 grading scale. Neurotoxicity was evaluated using a numeric rating scale (NRS) for pain intensity and experienced relief under the treatment of venlafaxine and using a neuropathic pain symptom inventory scale (NPSI) for the style of complaints. Patients who were diagnosed as mildly depressed according to the HOST anxiety and depression scale and who had grade 1 to 3 sensory neurotoxicity based on the NCI-CTCAE v. 4.03 grading scale, and who also reported ≥ 4/10 on a NRS were eligible. The primary end point was the rate of more than 75 % symptomatic relief under venlafaxine treatment. RESULTS: Two hundred six patients were included (82 % female, median age: 52.7 years). Most patients had breast, gynecologic, and colon cancer (93.4 %). Ninety-one patients who received venlafaxine and 115 patients as the control group were assessed for neurotoxicity every 3 weeks. Based on the NRS, a rate of more than 75 % symptomatic relief was 53.5, 58.3, and 45.2 % in venlafaxine arm versus 0, 0, and 0 % in the control arm in the first, second, and third visits, respectively. Side-effects of venlafaxine (n = 7) were grade 1-2 nausea/vomiting (3.2 %) and asthenia/somnolence (3.2 %) without grade 3-4 events. CONCLUSION: Venlafaxine has a significant clinical activity against taxane-oxaliplatin-induced acute neurosensory toxicity.
BACKGROUND: Oxaliplatin and taxane-induced neurosensory toxicity is dose-limiting and mostly presents with acute symptoms that affect the activities of daily living and overall quality of life. The objective of the present study is to assess the relief of acute neuropathy with venlafaxine treatment during the chemotherapy period. PATIENTS AND METHODS: In this retrospective case-control study, from January 2010 to February 2015, patients who experienced treatment with oxaliplatin and taxane-induced acute neurotoxicity were evaluated according to the NCI-CTCAE v. 4.03 grading scale. Neurotoxicity was evaluated using a numeric rating scale (NRS) for pain intensity and experienced relief under the treatment of venlafaxine and using a neuropathic pain symptom inventory scale (NPSI) for the style of complaints. Patients who were diagnosed as mildly depressed according to the HOST anxiety and depression scale and who had grade 1 to 3 sensory neurotoxicity based on the NCI-CTCAE v. 4.03 grading scale, and who also reported ≥ 4/10 on a NRS were eligible. The primary end point was the rate of more than 75 % symptomatic relief under venlafaxine treatment. RESULTS: Two hundred six patients were included (82 % female, median age: 52.7 years). Most patients had breast, gynecologic, and colon cancer (93.4 %). Ninety-one patients who received venlafaxine and 115 patients as the control group were assessed for neurotoxicity every 3 weeks. Based on the NRS, a rate of more than 75 % symptomatic relief was 53.5, 58.3, and 45.2 % in venlafaxine arm versus 0, 0, and 0 % in the control arm in the first, second, and third visits, respectively. Side-effects of venlafaxine (n = 7) were grade 1-2 nausea/vomiting (3.2 %) and asthenia/somnolence (3.2 %) without grade 3-4 events. CONCLUSION: Venlafaxine has a significant clinical activity against taxane-oxaliplatin-induced acute neurosensory toxicity.
Authors: Anna-Liisa Kautio; Maija Haanpää; Arto Leminen; Eija Kalso; Hannu Kautiainen; Tiina Saarto Journal: Anticancer Res Date: 2009-07 Impact factor: 2.480
Authors: Ravi D Rao; John C Michalak; Jeff A Sloan; Charles L Loprinzi; Gamini S Soori; Daniel A Nikcevich; David O Warner; Paul Novotny; Leila A Kutteh; Gilbert Y Wong Journal: Cancer Date: 2007-11-01 Impact factor: 6.860
Authors: Ravi D Rao; Patrick J Flynn; Jeff A Sloan; Gilbert Y Wong; Paul Novotny; David B Johnson; Howard M Gross; Samer I Renno; Mohammed Nashawaty; Charles L Loprinzi Journal: Cancer Date: 2008-06-15 Impact factor: 6.860
Authors: Daniel Ciampi de Andrade; Manoel Jacobsen Teixeira; Ricardo Galhardoni; Karine S L Ferreira; Paula Braz Mileno; Nathalia Scisci; Alexandra Zandonai; William G J Teixeira; Daniel F Saragiotto; Valquíria Silva; Irina Raicher; Rubens Gisbert Cury; Ricardo Macarenco; Carlos Otto Heise; Mario Wilson Iervolino Brotto; Alberto Andrade de Mello; Marcelo Zini Megale; Luiz Henrique Curti Dourado; Luciana Mendes Bahia; Antonia Lilian Rodrigues; Daniella Parravano; Julia Tizue Fukushima; Jean-Pascal Lefaucheur; Didier Bouhassira; Evandro Sobroza; Rachel P Riechelmann; Paulo M Hoff; Fernanda Valério da Silva; Thais Chile; Camila S Dale; Daniela Nebuloni; Luiz Senna; Helena Brentani; Rosana L Pagano; Ângela M de Souza Journal: Oncologist Date: 2017-06-26
Authors: Soo Youn Song; Young Bok Ko; Hyeun Kim; Geon Woo Lee; Jung Bo Yang; Ha Kyun Chang; Sang Mi Kwak; Jaeyun Jung; Siyeo Lee; Sun Yeul Lee; Heon Jong Yoo Journal: Medicine (Baltimore) Date: 2020-01 Impact factor: 1.817